Laronidase is a recombinant enzyme commercialized by JCR Pharmaceuticals, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Laronidase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Laronidase is expected to reach an annual total of $3 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Laronidase Overview

JR-171 is under development for the treatment of Hurler syndrome. The drug candidate is a recombinant blood brain barrier penetrating acid alpha-L iduronidase. It is administered by intravenous route and developed based on J-brain cargo technology and J-MIG system. The drug candidate is an enzyme replacement therapy.

JCR Pharmaceuticals Overview

JCR Pharmaceuticals (JCR) manufactures, sells, buys, imports, and exports pharmaceutical products, regenerative drugs and drug substances. It provides biopharmaceuticals in the field of regenerative medicine for the treatment of rare diseases. The company offers pharmaceuticals to treat growth hormone deficiency, Turner syndrome, adult growth hormone deficiency, small for gestational age, renal anemia in dialysis patients, and anemia of prematurity; and a regenerative medical product for acute graft-versus-host disease and other disorders. JCR is also involved in the purchasing, selling, import and export of medical devices and laboratory instruments. It operates subsidiaries in Japan, Brazil, Switzerland, and the US. JCR is headquartered in Ashiya, Hyogo, Japan.

The company reported revenues of (Yen) JPY51,082 million for the fiscal year ended March 2022 (FY2022), an increase of 69.8% over FY2021. In FY2022, the company’s operating margin was 36.9%, compared to an operating margin of 28.1% in FY2021. In FY2022, the company recorded a net margin of 28.4%, compared to a net margin of 22.9% in FY2021. The company reported revenues of JPY11,115 million for the third quarter ended December 2022, an increase of 86% over the previous quarter.

For a complete picture of Laronidase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.